Abstract：Objective To investigate the expression of galectin-3 in wounds and sera of patients with diabetic foot ulcer(DFU)so as to clarify the correlation between galectin-3 and DFU. Methods Fifty DFU patients with Wagner 1-2 stages and 20 wounded patients with normal blood glucose level (serving as the control group) were enrolled to obtain their tissues from the edge of the foot wound and sera from January 2015 to March 2016. The serum concentration of galectin-3 was detected by ELISA, and the expression of galection-3 in the tissues was detected by Western-blot . Results ELISA results showed that the serum concentration of galectin-3 was higher in the DFU group than in the wounded control group ((5.66±2.76)ng/mL vs. (4.25±1.94) ng/mL, P=0.04). Western-blot results indicated that the expression of galectin-3 in tissues from wound edge of the DFU group was enhanced. Conclusions Galectin-3 is highly expressed in the patients with DFU, and its high expression may contribute to the development of DFU.
[1] Jhamb S, Vangaveti VN, Malabu UH. Genetic and molecular basis of diabetic foot ulcers: clinical review[J]. J Tissue Viability, 2016, 25(4):229-236.
[2] Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12):1090-1101.
[3] Saccon F, Gatto M, Ghirardello A, et al. Role of galectin-3 in autoimmune and non-autoimmune nephropathies[J]. Autoimmun Rev, 2017, 16(1):34-47.
[4] Wang L, Guo XL. Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression[J]. Biomed Pharmacother, 2016, 78:165-171.
[5] Chin CW, Djohan AH, Lang CC. The role of cardiac biochemical markers in aortic stenosis[J]. Biomarkers, 2016, 21(4):316-327.
[6] Organization WH. Global report on diabetes[J]. Working Papers, 2016.
[7] Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischemia, infection and serious co-morbidity in patients with diabetic foot disease in Europe:baseline results from the Eurodiale Study[J]. Diabetologia, 2007, 50(1):18-25.
[8] van der Hoeven NW, Hollander MR, Yildirm C, et al. The emerging role of galectins in cardiovascular disease[J]. Vasc Pharmacol, 2016, 81:31.
[9] Tas F, Bilgin E, Tastekin D, et al. Clinical significance of serum galectin-3 levels in gastric cancer patients[J]. J Gastrointest Cancer, 2016, 47(2):182-186.
[10] Shimura T, Shibata M, Gonda K, et al. Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer[J]. Biomed Reports, 2016, 5(2):203-207.
[11] Aksan G, Gedikli Ö, Keskin K, et al. Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis?[J]. J Investig Med, 2016, 64(3):764-770.
[12] Yilmaz H, Cakmak M, Inan O, et al. Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor?[J]. JEndocrinol Invest, 2015, 38(5):527-533.
[13] Jin QH, Lou YF, Li TL, et al. Serum galectin-3:a risk factor for vascular complications in type 2 diabetes mellitus[J].Chinese Med J-Peking, 2013, 126(11):2109-2115.
[14] Li P, Liu S, Lu M, et al. Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance[J]. Cell, 2016, 167(4):973.
[15] Pugliese G, Iacobini C, Ricci C, et al. galectin-3 in diabetic patients[J]. Clin Chem Lab Med, 2014, 52(10):1413-1423.
2018, Vol. 25 
